Cargando…

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8(+) T cell dysfunction in melanoma patients

The paradoxical coexistence of spontaneous tumor antigen–specific immune responses with progressive disease in cancer patients furthers the need to dissect the molecular pathways involved in tumor-induced T cell dysfunction. In patients with advanced melanoma, we have previously shown that the cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fourcade, Julien, Sun, Zhaojun, Benallaoua, Mourad, Guillaume, Philippe, Luescher, Immanuel F., Sander, Cindy, Kirkwood, John M., Kuchroo, Vijay, Zarour, Hassane M.
Formato:	Texto
Lenguaje:	English
Publicado:	The Rockefeller University Press 2010
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947081/ https://www.ncbi.nlm.nih.gov/pubmed/20819923 http://dx.doi.org/10.1084/jem.20100637

Ejemplares similares

TIMs: central regulators of immune responses
por: Hafler, David A., et al.
Publicado: (2008)

Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes
por: Schmidt, Julien, et al.
Publicado: (2013)

Tim-3 mediates T cell trogocytosis to limit antitumor immunity
por: Pagliano, Ornella, et al.
Publicado: (2022)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2011)

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
por: Sakuishi, Kaori, et al.
Publicado: (2010)

Targeting STAT3 Abrogates Tim-3 Upregulation of Adaptive Resistance to PD-1 Blockade on Regulatory T Cells of Melanoma
por: Huang, Lili, et al.
Publicado: (2021)

Tim Protein Structures Reveal a Unique Face for Ligand Binding
por: Anderson, Ana C., et al.
Publicado: (2007)

Targeting multiple inhibitory receptors to reverse melanoma-induced T cell dysfunction
por: Zarour, Hassane M
Publicado: (2015)

Dysregulated T cell expression of TIM3 in multiple sclerosis
por: Koguchi, Ken, et al.
Publicado: (2006)

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
por: Bastacky, Melissa L., et al.
Publicado: (2021)

Tim3 binding to galectin-9 stimulates antimicrobial immunity
por: Jayaraman, Pushpa, et al.
Publicado: (2010)

Tim-2 regulates T helper type 2 responses and autoimmunity
por: Chakravarti, Sumone, et al.
Publicado: (2005)

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma
por: Augustin, Ryan C, et al.
Publicado: (2023)

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection
por: Jayaraman, Pushpa, et al.
Publicado: (2016)

PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors
por: Wang, Jaeyun Jane, et al.
Publicado: (2019)

Identification and isolation of high avidity tumor-specific CD8 T cells by experimentally assessing pMHC-TCR binding parameters with soluble pMHC complexes
por: Schmidt, Julien, et al.
Publicado: (2015)

A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma
por: Shaikh, Saba S., et al.
Publicado: (2022)

TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
por: Sakuishi, Kaori, et al.
Publicado: (2013)

Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients
por: Fortman, Dylan, et al.
Publicado: (2023)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
por: Tian, Tian, et al.
Publicado: (2021)

TIM-4 Identifies Effector B Cells Expressing An IL-23-Driven Proinflammatory Cytokine Module That Promotes Immune Responses
por: Ding, Qing, et al.
Publicado: (2023)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4(+) T Cells
por: Saleh, Reem, et al.
Publicado: (2019)

Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression
por: Yu, Muming, et al.
Publicado: (2017)

Upregulation of Tim‐3 is associated with poor prognosis in acute myeloid leukemia
por: Wu, Zhengwei, et al.
Publicado: (2022)

Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2015)

Effects of Epitope Modification on T Cell Receptor–Ligand Binding and Antigen Recognition by Seven H-2K(d)–restricted Cytotoxic T Lymphocyte Clones Specific for a Photoreactive Peptide Derivative
por: Kessler, Benedikt M., et al.
Publicado: (1997)

Expression of Self-antigen in the Thymus: A Little Goes a Long Way
por: Anderson, Ana C., et al.
Publicado: (2003)

Knock-down of the TIM/TIPIN complex promotes apoptosis in melanoma cells
por: Chakraborty, Abhijit, et al.
Publicado: (2020)

Identification ACTA2 and KDR as key proteins for prognosis of PD‐1/PD‐L1 blockade therapy in melanoma
por: Wang, Yuchen, et al.
Publicado: (2021)

PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015)

Elevation of Tim-3 and PD-1 Expression on T Cells Appears Early in HIV Infection, and Differential Tim-3 and PD-1 Expression Patterns Can Be Induced by Common γ-Chain Cytokines
por: Zhang, Zi-Ning, et al.
Publicado: (2015)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

Mast cell activation is enhanced by Tim1:Tim4 interaction but not by Tim-1 antibodies
por: Phong, Binh, et al.
Publicado: (2016)

Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8(+) antigen-specific T cells for adoptive immunotherapy
por: Lak, Shirin, et al.
Publicado: (2022)

TIM-3: a tumor-associated antigen beyond checkpoint inhibition?
por: Barth, Stefan, et al.
Publicado: (2022)

An IL-27/NFIL3 signaling axis drives Tim-3 and IL-10 expression and T cell dysfunction
por: Zhu, Chen, et al.
Publicado: (2015)

PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in Atherosclerosis
por: Qiu, Ming-Ke, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f7ld0rr92e5frnndvfh09th479